It seemed like a game of whack-a-mole — or whack-a-molecule, to be more precise. A microscopic compound would rise up from the murk of the inner ear, heralded as the molecule that might explain how we hear. Researchers would get excited. There would be news reports. Then, a paper would disprove the hypothesis and knock that promising protein back into obscurity.

For David Corey, that pattern is personal. He started tinkering with inner ear cells in 1975, when he was 24. Almost 30 years later, he moved his research into a Harvard Medical School office that had previously housed two Nobel prize winners: one who’d helped untangle our sense of sight, and the other our sense of smell. In 2004, he’d published his own breakthrough in Nature, detailing the discovery of a molecule in our ear cells that seemed to translate sound waves into electrical currents our brains can understand. Then, in 2006, it all fell apart. Mice born without the protein should have been deaf. But when he played a loud clapping-like noise for them, they flinched.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy